Accordingly, the level of NRF2 has been directly correlated with ferroptosis sensitivity, as increased expression of NRF2 prevents ferroptosis, whereas decreased NRF2 enhances the sensitivity of cancer cells to pro-ferroptotic agents [57], [59]. Here, NFE2L2 is linked to cancer.